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Short summary:  
We compared the incidence of suicidal behavior events between participants with 
high CD4 count who were started on ART immediately or at CD4 cell count below 
350 cell/mL. Participants with pre-existing psychiatric conditions and those started 
on efavirenz-based, but not other ART combinations, had increased risk of suicidal 
behavior. 
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Abstract 
 
Background: Randomized trials have shown increased risk of suicidality associated 
with efavirenz (EFV). The START trial randomized treatment-naïve HIV-positive adults 
with high CD4 cell counts to immediate versus deferred antiretroviral therapy (ART).   
 
Methods: The initial ART regimen was selected prior to randomization (“pre-
specified”). We compared the incidence of suicidal and self-injurious behaviour 
(“suicidal behavior”) between the immediate versus deferred ART groups using 
proportional hazards models, separately for those with EFV and other pre-specified 
regimens, by intention-to-treat, and after censoring participants in the deferred arm 
at ART initiation.  
 
Results: Of 4684 participants, 271 (5.8%) had a prior psychiatric diagnosis.  EFV was 
pre-specified for 3515 participants (75%); less often in those with psychiatric 
diagnoses (40%) than without (77%).  While the overall intention-to-treat 
comparison showed no difference in suicidal behavior between arms (53 events, 
hazard ratio [HR]=1.07, p=0.81), subgroup analyses suggest that initiation of EFV, but 
not other ART, is associated with increased risk of suicidal behavior. In particular, 
when censoring follow-up at ART initiation in the deferred group, the immediate 
versus deferred HR among those who were pre-specified EFV was 3.31 (p=0.03) and 
the HR among those with other pre-specified ART was 1.04 (p=0.93) (p=0.07 for 
interaction). Risk was higher among those with prior psychiatric diagnoses, 12.5 and 
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9.3 times among those with pre-specified EFV and other ART, respectively, in the 
immediate group.  
 
Conclusions: Participants who used EFV in the immediate ART group had increased 
risk of suicidal behavior compared to ART-naïve controls. Those with prior psychiatric 
diagnoses were at higher risk.  
 
Funding: The START study is primarily funded by the National Institute of Allergy and 
Infectious Diseases of the NIH. 
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Efavirenz (EFV) has been a preferred option for first-line anti-retroviral therapy (ART) 
and is recommended in the WHO guidelines for all HIV-positive adults and 
adolescents (1), preferably as part of a fixed-dose combination (2). EFV is usually well 
tolerated but neuropsychiatric adverse-effects can result in treatment switching (3) 
or serious clinical complications. A meta-analysis of four trials in ART-naïve patients 
showed an increased risk of suicidality in those randomized to EFV-based ART 
compared to other regimens (4). In contrast, several observational studies found no 
associations of EFV with suicidality (5-7), possibly because, consistent with some 
prescribing guidelines (8), providers avoided EFV in patients who were at increased 
risk of suicidality resulting in a higher proportion of high-risk participants in non-EFV 
control groups which might bias observational studies. 
 
The Strategic Timing of Antiretroviral Treatment (START) trial demonstrated clear 
clinical benefit of immediate ART by decreasing the risk of serious AIDS and serious 
non-AIDS conditions by 57% in HIV-positive adults with near-normal CD4 cell counts 
(9). In START, “suicidal behavior” was the second most frequent type of serious 
event reported and 75% of participants randomized to immediate ART initiation 
used EFV-based ART.  We investigated whether initiating EFV increased risk of 
“suicidal behavior” more than initiating other ART, by utilizing START’s randomized 
design to find appropriate control groups.    
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Methods 
 
Study design and participants 
The START trial has been described previously (9, 10). In brief, HIV-positive, ART-
naïve individuals with high CD4 cell counts and no previous AIDS-defining conditions 
were randomized to initiating ART immediately versus deferring ART until the CD4 
cell count dropped below 350 cells/µL or AIDS developed (Supplemental Appendix, 
Figure S1). Each participant’s ART regimen was selected prior to randomization 
(“pre-specified”) by site investigators from a table of recommended initial regimens 
(Supplemental Appendix, section 1). START enrolled between 2009 and 2013. This 
analysis uses data accrued through May 26, 2015, the day before the START study 
results were unblinded and participants in the deferred ART group were 
recommended starting ART (9).  
 
Outcomes 
The START study reported “serious events” that were not related to AIDS 
irrespective of exposure to ART. These included deaths, unscheduled hospitalizations 
and grade 4 Adverse Events according to the NIH Division of AIDS toxicity table (11) 
(Supplemental Appendix, Table S1). All serious events were coded using the Medical 
Dictionary for Regulatory Activities (MedDRA®), version 19.1, by staff blinded to 
treatment assignments and ART regimens. The primary endpoint for this analysis are 
events coded as the MedDRA high-level group term “suicidal and self-injurious 
behavior”, referred to as “suicidal behavior”. 
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Baseline Covariates 
Age, gender, HIV risk group, prior psychiatric diagnosis (major depression, bipolar 
disorder, or psychotic disorder including schizophrenia), and current use of 
psychotropic drugs (benzodiazepines, antidepressants, antipsychotic drugs 
[neuroleptics], other drugs for bipolar mood disorders, methadone, other prescribed 
opiates) were obtained by chart abstraction or participant self-report. History of 
recreational drug use (amphetamines, methamphetamines/ecstasy, cocaine, 
ketamine, opiates) and heavy alcohol consumption within the past month were 
estimated from a self-administered questionnaire (Supplemental Appendix, section 
2).    
 
Statistical analysis 
Our primary goal was to assess whether use of EFV-based ART regimens increased 
the risk of suicidal behavior, compared with no ART use, or with other ART.  To 
investigate whether participants who were pre-specified EFV prior to randomization 
had the same a-priori risk of suicidal behavior as those with other ART, we 
considered the follow-up in the deferred ART group accrued prior to ART initiation, 
and compared the two subgroups for the incidence of suicidal behavior using Kaplan-
Meier estimates and a log-rank test (Figure 1).  A direct comparison of participants 
who used EFV versus those who used other ART would be confounded by the 
differences in a-priori risk.  To avoid such bias, we used a series of intention-to-treat 
comparisons between the randomized immediate and deferred ART groups to assess 
the effect of EFV use (in the immediate ART group) versus an appropriate control 
group. First, we compared the incidence of suicidal behavior in the immediate versus 
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the deferred ART groups using Cox proportional hazards models, overall, and 
separately within the two subgroups of participants by pre-specified ART type (EFV-
based, and other ART) (Figure 2).  These treatment comparisons are protected by 
randomization, because the subgroups were defined before randomization. Because 
most participants in the immediate group started their pre-specified regimen (Figure 
3), the intention-to-treat comparisons within the two subgroups are an approximate 
comparison of immediate EFV (or other ART) use versus deferring EFV (or other 
ART). In the second analysis, we restricted follow-up to year 1, since only few 
participants in the deferred group initiated ART in the first year (Figure 3). This 
analysis provides a better approximation of comparing EFV (or other ART) use to no 
ART while maintaining the protection by randomization.  In the third analysis, in 
order to compare EFV (or other ART) use directly to no ART, we censored follow-up 
in the deferred group at ART initiation; in the immediate ART group, we started 
follow-up at ART initiation.  Consequently, in the “pre-specified EFV” (other ART) 
subgroup, all participants in the immediate ART group initiated EFV (other ART) at 
time 0, and were compared to similar participants in the deferred group without 
ART. In the “pre-specified other ART” subgroup, we also censored follow-up at any 
EFV initiation in the immediate group. For this third analysis, which is not protected 
by randomization, we provided Kaplan-Meier estimates of the cumulative 
proportions of participants with suicidal behavior.  The three analyses were repeated 
for participants with or without prior psychiatric diagnoses, because the rates of 
suicidal behavior were higher among those participants. 
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In all three analyses, we compared the hazard ratios (immediate versus deferred 
ART) across the two subgroups (pre-specified EFV or other ART) by including the 
interaction between the treatment group and subgroup indicators in expanded Cox 
proportional hazards models. To estimate the effect of EFV compared with other 
ART, we calculated the corresponding ratio of hazard ratios (immediate versus 
deferred ART) for the “pre-specified EFV” subgroup over the “pre-specified other 
ART” subgroup (Figure 2). 
 
Event rates were estimated without adjustments for baseline characteristics. 
However, proportional hazards models comparing immediate versus deferred ART 
were stratified by history of psychiatric diagnoses. We compared baseline 
characteristics between participants who were pre-specified EFV versus other ART 
using Kruskal-Wallis tests for medians and chi-squared tests for proportions.  We 
described ART use through follow-up by plotting the proportion of participants using 
any EFV, other ART, and no ART in one-month intervals, and by calculating the 
percentage of total follow-up time during which EFV, other ART, and no ART was 
used.   
 
To identify predictors for suicidal behavior with EFV use, we restricted the analyses 
to participants in the immediate ART group who were pre-specified and started EFV, 
and estimated associations in Cox proportional hazards models. Initially, we included 
baseline variables (age, sex, HIV risk group, race/ethnicity, geographic region [high vs 
low-middle income], prior psychiatric diagnoses, psychotropic drug treatment, 
recreational drug use, heavy alcohol use) and a time-updated indicator variable for 
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EFV use.  In the final model, we retained age, sex, HIV risk group, and the time-
updated EFV indicator, in addition to those baseline factors that were independently 
associated with the risk of suicidal behavior in the initial, model.  Using predictors 
with p<0.10 in the final model for EFV, we repeated the analyses for participants pre-
specified other ART.  For the strongest predictor (prior psychiatric diagnoses), we 
tested whether associations with suicidal behavior differed by pre-specified ART type 
in the immediate ART group by testing for an interaction between ART type and 
predictor.   
 
Statistical analyses were performed using SAS versions 9.3 and 9.4 (SAS Institute, 
Cary, NC) and R version 3 (12).  All tests are 2-sided; p-values <0.05 denote statistical 
significance.   
 
 
Results 
 
Baseline Characteristics 
The START study enrolled 4684 participants at 215 sites in 35 countries.  Baseline 
characteristics were described previously (9, 13).  The “pre-specified” ART regimen 
included EFV in 3515 (75%) participants. Table 1 shows the baseline characteristics 
by type of pre-specified ART.  Participants with pre-specified EFV less frequently 
lived in high-income countries (34% versus 81%), were less likely to be current 
smokers (29% versus 42%), and less likely to have used recreational drugs (24% 
versus 38%).  Within the two subgroups, the immediate and deferred treatment 
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groups were well-balanced for baseline characteristics (Supplemental Appendix, 
Table S2). 
 
Pre-existing psychiatric diagnoses were less common in those with pre-specified EFV 
compared to other ART (3.1% versus 13.9%), as was use of psychotropic medication 
(5.2% versus 16.8%) (Table 1). The prevalence of psychiatric conditions at baseline 
was higher in high-income regions (U.S.A., Europe and Australia) compared to low-
middle income regions (Latin America, Africa and Asia) (11% and 1.4%, respectively). 
 
ART use through follow-up 
Figure 3A shows the use of EFV and other ART over time in the immediate and 
deferred ART groups, separately for participants with pre-specified EFV and other 
ART.  Among those pre-specified EFV in the immediate ART group, 94% were using 
ART by month 4 and 82% were on EFV (Figure 3A, upper-left panel); in the deferred 
arm, median time to ART initiation was 3.2 years, 46% ever initiated ART, and 31% 
initiated EFV (upper-right panel).  Among those with other ART pre-specified, ART 
use in both treatment groups was slightly higher, and a few participants also used 
EFV (Figure 3A, lower panels). 
 
Figure 3B shows cumulative ART use as proportion of follow-up time accrued.  
Among those with EFV pre-specified, ART was used for 94% of follow-up time in the 
immediate group versus 26% in the deferred group, and EFV was used for 76% and 
15%, respectively.  Among those with other ART pre-specified, ART was used for 95% 
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and 35% of time in the immediate and deferred groups, respectively. EFV was used 
for 6% and 4% of time, respectively.  
 
Suicidal behavior 
Suicidal behavior was reported for 28 participants in the immediate ART group and 
25 in the deferred group over a mean follow-up of 3.2 years, rates of 0.39 and 0.34 
per 100 person-years (PY), respectively.  The estimated HR (immediate versus 
deferred group) was 1.07 (95% CI: 0.6 to 1.8); there was no evidence for a treatment 
difference (p=0.81).  Among those with EFV pre-specified, 19 participants in the 
immediate ART group reported suicidal behavior versus 12 in the deferred group, 
rates of 0.35 and 0.22 per 100 PY, respectively, (HR=1.38; 95% CI: 0.7 to 2.9) (Table 
2).  Among those with other ART pre-specified, 9 (rate 0.50 per 100 PY) and 13 
participants (rate 0.69 per 100 PY) had suicidal behavior, respectively (HR=0.74; 95% 
CI: 0.3 to 1.7).  The ratio between the HRs, comparing the pre-specified EFV 
subgroup versus the other ART subgroup for “excess risk” of suicidal behavior in the 
immediate group, was not significant (HR ratio=1.86, p=0.24).   
 
We repeated the analyses for the first year of follow-up only.  Among those with EFV 
pre-specified, the HR was 3.74 (95% CI 0.8-17.5; p=0.09), compared with HR=1.02 
among those with other ART pre-specified (Table 2).  However, event numbers were 
small in this analysis, confidence intervals were large, and there was insufficient 
evidence for heterogeneity between the sub-groups (HR ratio = 3.67, p=0.15).  
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In the third analysis, we compared EFV (or other ART) use to no ART, by starting 
follow-up in the immediate group at ART initiation, and censoring follow-up in the 
deferred group at ART initiation.  Among those with EFV pre-specified, 18 
participants (0.36 per 100 PY) experienced suicidal behavior in the immediate group 
(one event occurred in a participant who was excluded in this analysis because never 
used EFV), compared with 4 (0.10 per 100 PY) in the deferred group (HR=3.31; 95% 
CI: 1.1 to 9.9; p=0.03). Among those with other ART pre-specified, rates in both 
treatment groups were higher (0.56 and 0.66 per 100 PY), but the hazard ratio was 
1.04 (95% CI: 0.4 to 2.7, p=0.93).  The excess risk of suicidal behavior in the 
immediate ART group versus no ART was 3.18-fold higher among those with EFV pre-
specified compared with the other ART subgroup, but there was insufficient 
evidence for heterogeneity between subgroups (p=0.07) (Table 2). For the last 
comparison, Kaplan-Meier estimates for the cumulative proportion of participants 
with suicidal behavior are shown in Figure 4.   
 
Of the 53 “suicidal behavior” events, 3 were completed suicide, all in the deferred 
ART group and after ART initiation. Two of these participants had pre-existing 
depression and anxiety/depression and were treated for these. Both were on 
Truvada plus darunavir/ritonavir. The third participant had a history of alcohol 
abuse, and started EFV-based ART 18 months before the suicide. Table 3 shows the 
components of “suicidal behavior” by MedDRA® Preferred Term, for each of the 
comparisons in table 2.   
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The incidence of suicidal behavior was substantially higher among the 371 
participants with prior psychiatric diagnosis; among those pre-specified other ART, 8 
of 162 participants with prior psychiatric diagnoses experienced an event (1.7 per 
100 PY) compared with 14 of 1007 without diagnoses (0.5 per 100 PY) (p=0.003).  
Supplemental Tables S3 and S4 show the event rates and HRs from Table 2 for 
participants with and without prior psychiatric diagnoses, respectively.  Among the 
109 participants with prior psychiatric diagnoses who were pre-specified EFV, none 
experienced suicidal behavior in the deferred ART group, compared with 6 (2.7 per 
100 PY) in the immediate group after starting EFV (Table S3).   
 
Predictors of suicidal behavior 
A prior psychiatric diagnosis was the strongest predictor of suicidal behavior among 
participants in the immediate group who started ART, both among those who were 
pre-specified EFV, HR=12.5 (95% CI: 4.7 to 33.6, p<0.001) (Table 4), and those pre-
specified other ART, HR=9.3 (95% CI: 2.4 to 36.4, p=0.001) (Supplemental Table S5); 
there was no evidence for a difference by ART type (p=0.79 for interaction).  Among 
those who were pre-specified EFV, heavy alcohol and recreational drug use were 
independently associated with increased risk (HR of 4.6 and 2.6, respectively), while 
the risk decreased with age (HR=0.51 per 10 years older).  The time-updated 
indicator for EFV use was not associated with risk of suicidal behavior (HR=1.4, 
p=0.74); however, power for this variable was low because almost all participants 
started EFV shortly after randomization (Table 4).  Median time from EFV start to 
suicidal behavior was 10.2 months. 
 
14 
 
Discussion 
 
In START there was no overall difference between the immediate versus deferred 
ART groups in the incidence of suicidal behavior events. However, among 
participants whose pre-specified ART regimen contained EFV, those in the 
immediate arm who started EFV had higher risk of suicidal behavior (HR=3.31; 
95%CI: 1.19.9; p=0.03) compared to those who were randomized to the deferred 
arm and were not yet using any ART. Conversely, among participants who were pre-
specified other ART, there was no excess risk of suicidal behavior in the immediate 
ART group (HR=1.04).  This is consistent with a post-hoc meta-analysis that 
combined data from four ART-naïve trials (4). In contrast, cohort analyses and data 
extracted from regulatory agencies databases have failed to observe any excess risk 
of suicidality associated with EFV (5-7). Observational studies comparing EFV use to 
other ART are unreliable, however, because EFV is often avoided for patients with 
elevated risk of suicidal behavior, resulting in higher a-priori risk of suicidal behavior 
in the other ART group. This higher a-priori risk was evident in the START study 
(Figure 1).  We minimized bias by utilizing the randomized design of the study to 
identify control groups for EFV (or other ART) prior to randomization.  
 
In the general population, patients with severe depression and other serious 
psychiatric conditions are at higher risk for suicidality (14-16). In our study, the 
strongest predictor of suicidal behavior in the immediate ART group was a pre-
existing psychiatric diagnosis, both among those using EFV and those with other ART. 
Given the higher absolute risk of suicidal behavior among those with psychiatric 
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conditions, the association between EFV exposure and suicidal behavior supports the 
recommendation in national and regional guidelines to avoid prescribing EFV to 
patients with past or current psychiatric conditions (8, 17, 18). Recreational drugs 
use, including alcohol, was also independently associated with suicidal behavior, 
which is also consistent with findings in the general population and those with other 
chronic conditions, particularly at younger age (15, 19, 20).  
 
In a recent systematic review and meta-analysis, a higher incidence of severe 
neuropsychiatric adverse events but not suicidality was observed in ART-naïve adults 
randomized to EFV-based ART compared to other regimens. However, there were no 
completed suicides in the meta-analysis studies and the overall rate of suicidal 
ideation was extremely low (0.6%), affecting their power to investigate differences 
between groups (21).  
 
Screening for psychiatric conditions (mainly depression) before prescribing EFV could 
reduce the risk of suicidality. However, screening may not be feasible or affordable, 
particularly in low-middle income countries where EFV continues to be frequently 
used in first-line ART. The Encore1 Trial reported a lower rate of EFV-related adverse 
events in patients treated with reduced compared to standard doses (22), suggesting 
that lower doses of EFV may provide a better safety profile. 
 
The main strengths of our study are the use of START’s randomized design, and the 
standardized reporting of serious suicidal behavior events.  Our study had several 
limitations. First, this is a post-hoc analysis of a trial in which EFV exposure was not 
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the randomized intervention. However, by comparing the immediate versus 
deferred treatment groups within subgroups by pre-specified ART type, we 
estimated the effect of EFV (and other ART) versus randomized control groups, thus 
minimizing selection bias.  Second, not all participants in the immediate group 
started their pre-specified regimen, and some discontinued pre-specified EFV. 
Adherence overall was high, however (Figure 3).  Third, participants in the deferred 
group gradually started ART; while we censored follow-up at ART start in the third 
analysis, this censoring compromises the protection by randomization. Fourth, NRTIs 
differed between the EFV and other ART groups.  Finally, the number of events was 
low, which limited the power; therefore, results need to be interpreted with caution.   
 
In conclusion, in START, ART-naïve participants using EFV in the immediate ART 
group had an increased risk of suicidal behavior compared to ART naïve controls. 
Pre-existing psychiatric conditions were the strongest predictor of suicidal behavior. 
Therefore, screening for major psychiatric conditions before EFV initiation would be 
advisable.  
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Table 1. Baseline characteristics by pre-specified ART regimen. 
  EFV + NRTIs 
(n=3515) 
Other ART
a
 + 
NRTIs 
(n=1169) P-valueb 
Total 
(n=4684) 
Age, median years [IQR] 36 [29, 43] 36 [29, 45] 0.010 36 [29, 44] 
Female, n (%) 995 (28.3) 262 (22.4) <0.001 1257 (26.8) 
Race, n (%)         
Asian 349 (9.9) 39 (3.3) <0.001 388 (8.3) 
Black 1158 (32.9) 250 (21.4) <0.001 1408 (30.1) 
Latino/Hispanic 527 (15.0) 110 (9.4) <0.001 637 (13.6) 
White 1339 (38.1) 748 (64.0) <0.001 2087 (44.6) 
Other 142 (4.0) 22 (1.9) <0.001 164 (3.5) 
Geographic region, n (%)         
Africa 897 (25.5) 102 (8.7) <0.001 999 (21.3) 
Asia 326 (9.3) 30 (2.6) <0.001 356 (7.6) 
Australia 51 (1.5) 58 (5.0) <0.001 109 (2.3) 
Europe and Israel 871 (24.8) 668 (57.1) <0.001 1539 (32.9) 
South America 1086 (30.9) 88 (7.5) <0.001 1174 (25.1) 
United States 284 (8.1) 223 (19.1) <0.001 507 (10.8) 
Income region, n (%)         
High (US/Europe/Australia)  1206 (34.3) 949 (81.2) <0.001 2155 (46.0) 
Low-moderate (Latin 
America/Africa/Asia) 
2309 (65.7) 220 (18.8) <0.001 2529 (54.0) 
Likely mode of HIV infection, n (%)         
Sexual contact with same sex 1831 (52.1) 756 (64.7) <0.001 2587 (55.2) 
Sexual contact with opposite sex 1466 (41.7) 322 (27.5) <0.001 1788 (38.2) 
Injection drug use 21 (0.6) 43 (3.7) <0.001 64 (1.4) 
Blood products/other/unknown 197 (5.6) 48 (4.1) 0.046 245 (5.2) 
Time since HIV diagnosis,  
 median years  [IQR] 
1.0 [0.3, 3.1] 1.1 [0.4, 3.0] 0.068 1.0 [0.4, 3.1] 
CD4
c
, median cells/µL [IQR] 
651 [583, 
768] 
652 [585, 755] 0.753 651 [584, 765] 
HIV RNA, median copies/mL [IQR] 
12225 
 [2879, 
41562] 
14304  
[3738, 47703] 
0.022 
12761 
 [3025, 43482] 
Current smoker, n (%) 1012 (28.8) 487 (41.7) <0.001 1499 (32.0) 
Pre-specified ART regimen, n (%)         
EFV + NRTIs 3515 (100.0) 0 (0.0) <0.001 3515 (75.0) 
Other NNRTI not EFV + NRTIs 0 (0.0) 171 (14.6) <0.001 171 (3.6) 
PI + NRTIs 0 (0.0) 815 (69.7) <0.001 815 (17.4) 
INSTI + NRTIs 0 (0.0) 183 (15.7) <0.001 183 (3.9) 
Psychiatric diagnosis or current 
psychotropic drug treatment, n (%) 
224 (6.4) 260 (22.2) <0.001 484 (10.3) 
Prior psychiatric diagnosis
d
 109 (3.1) 162 (13.9) <0.001 271 (5.8) 
Any psychotropic drug use 183 (5.2) 196 (16.8) <0.001 379 (8.1) 
Antidepressants 120 (3.4) 150 (12.8) <0.001 270 (5.8) 
Benzodiazepines 62 (1.8) 50 (4.3) <0.001 112 (2.4) 
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Antipsychotic drugs (neuroleptics) 15 (0.4) 19 (1.6) <0.001 34 (0.7) 
Other drugs for bipolar mood 
disorder 
5 (0.1) 13 (1.1) <0.001 18 (0.4) 
Methadone 1 (0.0) 8 (0.7) <0.001 9 (0.2) 
Other opiates 18 (0.5) 25 (2.1) <0.001 43 (0.9) 
Ever use of recreational drugs
e
, n (%) 858 (24.4) 442 (37.8) <0.001 1300 (27.8) 
Heavy alcohol use, n (%) 155 (4.4) 45 (3.8) 0.41 200 (4.3) 
 
 
 
        
a 
Ritonavir-boosted PI, INSTI, or NNRTI other than EFV. 
b
 P-values are for comparisons between the EFV+NRTIs and Other ART + NRTIs groups.  Medians 
were compared using Kruskall-Wallis tests, percents were compared using chi-squared tests.  
c
 Average of two screening values 
d
 Including major depression, bipolar disorder, psychotic disorder including schizophrenia.  These 
diagnoses were not collected separately. 
e
 Amphetamines and methamphetamines/ecstasy, cocaine, ketamine and opiates. 
 
ART = antiretroviral therapy; EFV = efavirenz; INSTI = integrase strand transfer inhibitor; IQR = inter 
quartile range; NNRTI = non-nucleoside reverse transcriptase inhibitor; NRTI = nucleoside reverse 
transcriptase inhibitor.   
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Table 2. Suicidal and self-injurious behavior, by randomization arm and pre-specified ART groups; Cox proportional hazards models.  
 
  N 
Immediate ART Deferred ART 
HR
a
 95% CI P 
HR 
Ratio
b
 
Int. P
c
 No. of 
pts with 
events 
Rate 
per 100 
PY 
No. of 
pts with 
events 
Rate 
per 100 
PY 
Intention to treat (ITT) analysis, 
mean follow-up 3 years 
        
 
         EFV pre-specified 3515 19 0.35 12 0.22 1.38 (0.7, 2.9) 0.39 
1.86 0.24 
        Other ART pre-specified 1169 9 0.50 13 0.69 0.74 (0.3, 1.7) 0.49 
ITT analysis, follow-up truncated 
at 1 year after randomization 
        
 
        EFV pre-specified 3515 9 0.52 2 0.11 3.74 (0.8, 17.5) 0.09 
3.67 0.15 
       Other ART pre-specified 1169 7 1.25 7 1.19 1.02 (0.4, 2.9) 0.96 
Censoring deferred arm 
participants at ART initiation  
        
 
 
      EFV pre-specified
d
 3394 18 0.36 4 0.10 3.31 (1.1, 9.9) 0.03 
3.18 0.07 
      Other ART pre-specified
e
 1137 9 0.56 8 0.66 1.04 (0.4, 2.7) 0.93 
 
a
 HR(Immediate/Deferred), estimated in Cox proportional hazards models, stratified by history of psychiatric diagnosis.   
b
 Ratio of HRs (Immediate/Deferred) within the EFV pre-specified subgroup over the Other ART pre-specified subgroup.   
c
 P-value for the interaction between indicators for treatment group and pre-specified ART regimen; compares HRs (Imm/Def) between subgroups by pre-specified ART. 
d
 Of these events, 6 and 0, in the immediate vs deferred arms, respectively, occurred among 100 participants with prior psychiatric diagnoses. The immediate group excludes 
participants who did not start ART.  Follow-up time starts at EFV start date.  Of the 3515 participants with EFV in the pre-specified regimen, 117 in the immediate arm were 
excluded (32 never started ART, 85 never used EFV), and 4 in the deferred arm were excluded (3 started ART at randomization, 1 participant was lost to follow-up at 
randomization).   
e
 Of these events, 5 and 2, in the immediate vs deferred arms respectively, occurred among 161 participants with prior psychiatric diagnoses. Of the 1169 participants without 
EFV in the pre-specified regimen, 32 were excluded (in the immediate group, 7 never started ART, and for 25, the first ART regimen contained EFV). The immediate group 
excludes participants who did not start ART.  Follow-up time starts at ART start date and was censored at EFV start. 
 
 
ART=antiretroviral therapy; CI=confidence interval; EFV=efavirenz, HR=hazard ratio; NRTI=nucleoside reverse transcriptase inhibitor. 
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Table 3. Number of participants with “suicidal and self-injurious behavior” included in each of 
the three analyses in Table 2, and the composition of these events by MedDRA Preferred 
Terms. 
 
  Complete 
Follow-up,  
ITT Analysis  
First Year,  
ITT Analysis 
 
Deferred Arm 
Censored at ART 
Initiation
a
 
  Imm. Def. Imm. Def. Imm. Def. 
Suicidal Behavior Events 
All participants  28 25 
 
16 9 
 
27 12 
EFV+NRTIs pre-specified 19 12 9 2 18 4 
Other ART+NRTIs pre-specified 9 13 7 7 9 8 
        
Breakdown of Suicidal Behavior by MedDRA Preferred Term 
All participants Completed 
suicide 
0 3 
 
0 0 
 
0 0 
 Intentional self-
injury 
0 1 0 0 0 0 
 Self-injurious 
ideation 
0 1 0 1 0 1 
 
Suicidal ideation 10 6 4 1 10 3 
 
Suicide attempt 18 14 12 7 17 8 
 
EFV+NRTIs 
 pre-specified 
Completed 
suicide 
0 1 
 
0 0 
 
0 0 
 Intentional self-
injury 
0 1 0 0 0 0 
 
Suicidal ideation 6 3 1 1 6 2 
 
Suicide attempt 13 7 8 1 12 2 
 
Other+NRTIs 
pre-specified 
Completed 
suicide 
0 2 
 
0 0 
 
0 0 
 Self-injurious 
ideation 
0 1 0 1 0 1 
 
Suicidal ideation 4 3 3 0 4 1 
 
Suicide attempt 5 7 4 6 5 6 
 
a
 In this analysis, follow-up in the immediate ART group is started at EFV (ART) initiation, 
which excludes participants who did not start EFV (ART) or had experienced suicidal 
behavior before initiating EFV (ART).   
 
ART=antiretroviral therapy, EFV=efavirenz, NRTI=nucleoside reverse transcriptase inhibitor. 
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Table 4. Factors associated with suicidal and self-injurious behavior among participants in the immediate ART group who were pre-specified EFV+NRTIs, 
and who started ART. 
  
Multivariate analysis
a
 
HR 95% CI P-value 
Age (per 10 yrs older) 0.51 (0.29, 0.89) 0.018 
Gender & risk group 
            Female vs male 0.68 (0.19, 2.47) 0.55 
         MSM vs other male 0.49 (0.15, 1.59) 0.23 
Prior psychiatric diagnosis
b
 12.49 (4.65, 33.59) <0.001 
Recreational drug use, ever 2.58 (0.96, 6.95) 0.06 
Heavy alcohol use 4.62 (1.46, 14.61) 0.009 
EFV started (time-updated)
c
 1.42 (0.18, 11.08) 0.74 
No. of participants  1723  
No. of suicidal behavior events  19  
 
a
 HRs from one multivariate Cox proportional hazards regression model with all listed variables. 
b
 Diagnosis of major depression, bipolar disorder, or psychotic disorder including schizophrenia  
c
 Indicator variable, switches from 0 to 1 at the date of EFV start (if ever). 
 
Number in group (number of events) for categorical variables: female=484 (3); MSM= 909 (12); other male=330 (4); prior psychiatric diagnosis= 70 (9); ever 
use of recreational drugs=409 (11); heavy alcohol use=76 (4). 
 
 
ART=antiretroviral therapy; CI=confidence interval; EFV=efavirenz, HR=hazard ratio; MSM=men who have sex with men; NRTI=nucleoside reverse 
transcriptase inhibitor. 
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Figure 1. Kaplan-Meier estimates of the cumulative percent of participants with suicidal or 
self-injurious behavior in the deferred ART group prior to any ART use, within subgroups by 
pre-specified ART type (EFV versus other ART).  Follow-up is censored at ART initiation.  
The difference between the curves (p<0.001) indicates that participants who were pre-
specified EFV-containing regimens had a lower a-priori risk of suicidal behavior compared 
with those pre-specified other ART. 
 
 
 
 
ART = antiretroviral therapy; EFV=efavirenz; NRTI = nucleoside reverse transcriptase 
inhibitor; PY = person years 
  
27 
 
 
 
              
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
4684 HIV-positive, ART-naive adults with  
CD4+ cell counts > 500 µL 
Randomization 1:1  
in START 
Randomization 1:1  
in START 
Subgroup: 
Participants who were pre-specified*  
Other ART + 2NRTIs 
(n=1169) 
 
Subgroup: 
Participants who were pre-specified*  
EFV + 2NRTIs 
(n=3515) 
 
Study Design: The study is a post-hoc analysis of “suicidal or self-injurious behavior”. 
The outcome consists of all events that were reported as “serious event” and were 
classified under the MedDRA® High-Level Group Term “suicidal and self-injurious 
behavior”.  In START, “serious events” were reported throughout follow-up, irrespective of 
ART use. 
 
*  ART regimens were pre-specified by the provider in consultation with participants and 
reported prior to randomization.  ART was pre-specified prior to randomization to 
enable randomized comparisons of immediate versus deferred use of specific drugs, by 
restricting analyses to those who were pre-specified the drug(s). 
 
Immediate 
ART Group 
(n=570) 
Deferred  
ART Group 
(n=599) 
Ratio HREFV/HROther 
compares EFV versus “Other ART” 
 
Hazard ratio, HREFV, estimates the 
effect of immediate EFV versus 
deferring EFV 
 
Immediate 
ART Group 
(n=1,755) 
Deferred  
ART Group 
(n=1760) 
Hazard ratio, HROther, estimates 
the effect of immediate “Other 
ART” versus deferring “Other ART” 
 
28 
 
 
Figure 3. ART and EFV use in the immediate and deferred ART groups, within subgroups by 
pre-specified ART type.  (A) Percent of participants using ART and EFV. (B) Percent of 
follow-up time during which ART and EFV were used. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
ART = antiretroviral therapy; EFV=efavirenz; NRTI = nucleoside reverse transcriptase 
inhibitor 
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Figure 4. Kaplan-Meier estimates of the cumulative percent of participants with suicidal or 
self-injurious behavior, within subgroups by pre-specified ART type.  In the deferred ART 
group, follow-up is censored at ART initiation.  (A) Kaplan-Meier estimates for participants 
who were pre-specified EFV-containing ART regimens.  In the immediate ART group, follow-
up time is started at EFV initiation, excluding 116 (6.6%) participants who never initiated EFV.  
(B) Kaplan-Meier estimates for participants whose pre-specified regimen did not contain EFV.  
In the immediate group, follow-up time is started at ART initiation, excluding 32 participants 
who never initiated ART or whose first regimen contained EFV; for the 31 participants who 
started EFV, follow-up is censored at EFV start.   
 
 
 
 
ART = antiretroviral therapy; EFV=efavirenz; NRTI = nucleoside reverse transcriptase 
inhibitor 
 
 
